There’s a powerful new tool to reduce the harm cancer inflicts: actinium-225, which can be attached to molecules to target cancer in the human body. Tested in worldwide clinical trials against advanced metastatic prostate cancer, the radioisotope has proven effective in eliminating cancers.
Researchers have demonstrated the production, purification, and potential application of cerium-134. The isotope decays into lanthanum-134, which is useful for positron emission tomography (PET) imaging. The results mean that cerium-134 could support medical treatments based on actinium-225 or thorium-227.
One isotope of the extremely rare element Astatine has shown promise in the treatment of malignant brain tumors, ovarian cancer, advanced blood and lymph system cancers. However, because of its short half-life, scientists need a rapid system with high yield to recover the isotope, At-211, for medical use. Scientists have developed a new purification system that results in a high purity, high yield recovery of At-211.
Scientists have developed a new system for producing radioisotopes for cancer therapy. The system uses a simple radionuclide generator to repeatedly separate thorium-226 from its longer-lived parent isotope, uranium-230. The uranium-230/thorium-226 pair has the unique advantage of emitting multiple alpha particles as they decay, delivering more destructive energy to cancer cells.